Fig. S7.

SC treated with recombinant CXCL12 exhibit alterations in pain-associated molecular mediators. hSC were treated for 24 h with human recombinant CXCL12 (10 ng/mL) and subsequently were analyzed for the mRNA expression of 84 different pain-related targets. In comparison with solvent-treated control SC, CXCL12 treatment resulted in at least threefold regulation in the expression of 17 targets listed on the right; up-regulated targets are circled in red; down-regulated targets are circled in blue. Alterations in six of these targets were associated with a potentially proalgesic outcome; the remaining 11 targets were associated with a potentially analgesic outcome. The scatter plot, heatmap, and table of targets were generated via the online Qiagen Data Analysis Center.